Prime Medicine logo

Prime Medicine Funding & Investors

Cambridge, MA

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.

https://primemedicine.com/

Total Amount Raised: $330,000,000

Prime Medicine Funding Rounds

  • Undisclosed

    $15,000,000

    Undisclosed Investors

    Cystic Fibrosis Foundation
  • IPO

    Unknown

  • Series B

    $200,000,000

    Series B Investors

    GV
    PSP Investments
    Redmile Group
    Newpath Management
    Samsara BioCapital
    Cormorant Asset Management
    Arch Venture Partners
    Moore Strategic Ventures
    F-Prime Capital
    T. Rowe Price
    Casdin Capital
    Arrive
  • Series A

    $115,000,000

    Series A Investors

    Arch Venture Partners
    F-Prime Capital
    GV
    Newpath Management
    Arrive
Funding info provided by Diffbot.